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The oxygen cost diagram (OCD) is a simple scale for quantifying a patient’s evaluation of his tolerance to exercise 
frequently used in clinical trials; it has been shown to be well correlated with objective measures of capacity of 
ambulation such as the 6 min walk test (6’ W). This study aimed to determine whether the OCD accurately depicts 
changes in capacity of ambulation either quantitatively or qualitatively. 
OCD ratings were analysed at baseline and after a 1 yr follow-up, in patients treated by non-invasive home 
mechanical ventilation, as well as objective measurements of pulmonary function [forced expiratory volume in 1 set 
(FEV& forced vital capacity (FVC), arterial blood gases], physical autonomy (6’ W), resting dyspnoea (Borg scale) 
and scores for anxiety or depressive disorders (HAD). 
Forty-five patients (24 male, 21 female, aged 62 f 16 years, mean FEV1: 38 + 17% of predicted) were evaluated at 
baseline. OCD ratings were significantly correlated with 6 min walking distance (PC O.OOOl)-although with a large 
variability around the regression line-but not with resting dyspnoea (Borg). Patients were re-evaluated after 
352+90 days. Changes in OCD ratings were not significantly correlated with changes in FEV,, FVC, PaOz, 
PaC02, 6’ W, HAD scores or resting dyspnoea; furthermore-albeit for Borg scores--changes in OCD did not 
reflect the trend of changes in these parameters. 
These results show that although OCD ratings are well correlated with results of a 6’ W test, they cannot be used 
to extrapolate individual performances, because of a large variability around the regression line; furthermore, 
changes in the OCD over 1 yr did not depict objective changes in 6’ W test results, either quantitatively or 
qualitatively. The use of the OCD in clinical trials should be limited to the description of the patient’s perception of 
exercise tolerance, as a component of health-related quality of life, with the awareness of possible discrepancies 
between changes in objective performances and changes in OCD ratings. 
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Introduction 
The oxygen cost diagram (OCD) initially published by 
McGavin et al. (1) is a single 100 mm long vertical line with 
daily activities listed beside it, in order of increasing 
metabolic and ventilatory requirements (oxygen cost) 
(Fig. 1). Patients are asked to indicate on the diagram the 
point above which they believe their breathlessness will not 
allow them to go (1). The OCD is therefore the expression 
of the patient’s own evaluation of tolerance to physical 
activity (or handicap), and capacity to perform everyday 
chores (shopping, bedmaking, etc.). It is described as a 
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‘disease-specific’ health-related quality of life (HRQL) 
instrument (2). 
The OCD has been widely used to analyse response to 
treatment in clinical trials, or to follow the progression of 
disease. Indeed, the OCD has been used as a clinical 
endpoint in studies assessing the subjective and objective 
benefit of theophylline (3,4), bronchodilators (5), combina- 
tions of bronchodilators and theophylline (6,7), inhaled 
corticosteroids (8,9), diazepam or promethazine (10) on 
dyspnoea in chronic obstructive pulmanary disease COPD 
or asthmatics, and the effect of angiotensin-converting 
enzyme (ACE) inhibitors in subjects with chronic heart 
failure (11). The OCD has also been used in descriptive or 
comparative studies of specific groups of patients with 
respiratory impairment (12-15). 
OCD ratings have shown moderate but significant 
correlations with spirometric measurements, arterial blood 
gases or measurements of respiratory muscle strength, 
maximal oxygen consumption (VOZ max), and CO 
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FIG. 1. The oxygen cost diagram, as described by 
McGavin et al. (1). 
diffusion (4,15-l 8). The strongest correlations reported 
however were between OCD scores and results of standar- 
dized 6 min or 12 min walk tests (6’ W) (1,13,16). 
Some authors suggest however that, in clinical trials, the 
OCD has shown moderate reproducibility and that it is less 
responsive than other dyspnoea scores such as the 
transition dyspnoea index (TDI) or the Chronic Respira- 
tory Disease Questionnaire (CRQ) (7,19). The present 
study aimed to determine whether the OCD accurately 
reflects changes in physical performance by analysing 
prospectively changes in functional parameters, 6’ W tests 
and dyspnoea ratings in patients treated by non-invasive 
home mechanical ventilation (NIHV) for predominantly 
restrictive pulmonary disorders. 
Patients and methods 
Since 1994, all patients treated with non-invasive home 
mechanical ventilation (NIHV) in our referral area have 
been included in a database and followed prospectively. 
NIHV had been initiated because of hypercapnic respira- 
tory failure, and all patients suffered from respiratory 
diseases accepted as well-established indications for NIHV 
(20). Patients were equipped with either volumetric 
ventilators (n = 18, Lifecare PLVIOOa, Eole II@, Dragger 
EV 800@, Medezin Technik, 6341 BAAR, Switzerland), or 
barometric ventilators (Respironics BiPAP S or STa, 
Medezin Technik), the choice depending on efficacy in 
correction of arterial blood gases and patient comfort. 
Patients included in the database undergo periodical, 
comprehensive evaluations at least once a year. These 
evaluations are performed electively, the patients being in a 
stable clinical condition. 
The database includes lung function tests, arterial blood 
gases with and without ventilator, dyspnoea scores (Borg 
scale and OCD) and scores for emotional disorders; 
information was recorded on Filemaker Pro@ 2.1 software 
(Claris Corporation, Santa Clara, California U.S.A.). The 
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present study analysed OCD ratings at baseline (i.e. at first 
elective evaluation after initiation of NIHV) and after a 1 yr 
follow-up, and correlations with objective measurements of 
pulmonary function and physical autonomy. Patients with 
normal OCD ratings (i.e. above 70) were excluded. 
LUNG FUNCTION TESTS 
Forced expiratory manoeuvres were recorded with a 
Vitalograph Alpha@ spirometer (MED: 8050, Zurich, 
Switzerland). Values recorded were the best of three 
consecutive manoeuvres, as recommended by the American 
Thoracic Society (ATS) standards (21). Reference values 
were published by Quanjer et al. (22). Arterial blood gases 
were measured by puncture of the radial artery during 
room air breathing, after at least 6 h without NIHV (Gas 
analyser: ABL 330 @, Copenhagen, Denmark). 
EXERCISE TOLERANCE 
A standardized 6-min walk test (6’ W) was performed in a 
50 m-long corridor, as described by McGavin et al. (23). 
Patients were asked to walk at the fastest pace they thought 
they could maintain for 6 min, without further verbal 
encouragement. In our institution, 6’ W tests are performed 
in very standardized conditions (location, personnel, 
absence of verbal stimulation). 
ESTIMATION OF DYSPNOEA AND 
PHYSICAL DISABILITY 
Resting dyspnoea was estimated by the patient with a Borg 
scale, a vertical linear 20 cm scale labelled from O-10, with 
corresponding verbal expressions of progressively increas- 
ing perceived intensity (higher values indicate more severe 
dyspnoea) (24). The Borg scale was preferred to a simple 
visual analogue scale (VAS) because of a better between- 
test repeatability of Borg scores (25). The OCD-a 100 mm 
weighted vertical visual analogue scale-was used to 
quantify the patient’s evaluation of his tolerance to exercise. 
(Fig. 1). The OCD lists everyday activities in order of 
increasing metabolic demand. The scale was submitted to 
the patients by the same investigators over the whole study 
period: patients were asked to note on the scale the effort 
above which they thought their breathlessness would not 
allow them to go (1). 
SCREENING FOR EMOTIONAL 
DISTURBANCES 
The ‘Hospital Anxiety and Depression’ (HAD) question- 
naire was used to screen for anxiety or depression; it 
contains 14 multiple choice questions; seven are oriented 
towards detection of anxiety disorders and seven towards 
detection of depression (26). The validated French version 
was used (27). The authors suggest scoring as follows: < 8: 
no evidence ,of depression; 8-10: suggestive of depression or 
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anxiety; > 10: abnormal values with a high specificity for 
anxiety or depressive disorders. 
STATISTICS 
Spearman’s rank correlation was used to test for associa- 
tion between OCD ratings and ordinal or interval data. 
McNemar’s test was used to compare trends between OCD 
changes and other recorded parameters. Statview 4.1 
software for Macintosh (Abacus Concepts, Berkeley, 
California, U.S.A.) was used for statistical analysis. Values 
are mean f SD unless otherwise stated. 
Results 
Forty-five patients (24 male, 21 female) were included for 
baseline analysis. These patients suffered from predomi- 
nantly restrictive disorders: kyphoscoliosis (n = 1 l), obesity- 
hypoventilation syndrome (n = 17), neuro-muscular dis- 
eases (n = 4) and post-tuberculosis syndrome (n = 8). Three 
patients suffered from severe bronchiectasis; two patients 
had severe hypercapnic COPD. Patients were aged 62f 16 
years (mean f SD, range: 20-80); mean body-mass index 
(BMI) was: 29f9.5 kg m-’ (range:12-50); pulmonary 
function tests were: forced expiratory volume in 1 set 
(FEVi) (% of predicted): 38 ) 17 (18-88); forced vital 
capacity (FVC) (% of predicted): 5Oi21 (18-92); arterial 
oxygen tension (PaOz): 83Ifr 1.6 kPa (5.3-11.7); arterial 
carbon dioxide tension (PaCOz): 6.4* 1.0 kPa (4.9-9.3); 
pH: 7.4OkO.03 (7.35-7.48); 6’ walk test: 327$96 m (40- 
469). HAD scores for anxiety were: 4.2* 3.5, and for 
depression: 5.6f 3.4; two patients had scores above 10 
indicating an anxiety disorder and four had scores 
indicating depression. Resting dyspnoea scores (Borg) were: 
2.02 1.4 (O-6); OCD scores were: 50+ 12 (28-70). 
Correlation between OCD and baseline data is shown in 
Table 1. There was no correlation between OCD and BMI. 
Correlation with distance walked during standardized 6’ W 
tests was highly significant (rho ~0.65, P<O.OOOl), as 
shown in Fig. 2, with however a wide variability of 
individual values around the regression line. r2 was 0.437. 
OCD was also strongly correlated with anxiety scores 
(HAD A: rho = -0.59, P= 0.0003) 
FOLLOW-UP DATA 
All patients were re-evaluated after 352 f 90 days. Pulmon- 
ary function tests at follow-up visit were: FEVi (% of 
predicted): 38.5 f 17 (range: 15-79); FVC (% of predicted): 
51f22 (16-95); PaOz: 7.9+ 1.8 kPa (5.2-12.8); PaC02: 
6.1 iO.9 kPa (4.7-8.4); pH: 7.39f0.02 (7.33-7.45); 6’ walk 
test: 319+ 101 m (103-500). HAD scores for anxiety were: 
4.7f3.8, and for depression: 6.3 k3.6. Resting dyspnoea 
scores (Borg) were: 1.212.0 (O-7); OCD scores were: 
51& 15 (25-79). 
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FIG. 2. Relationship between ‘oxygen cost diagram’ 
ratings and distance walked during a standardized 6 min 
walk test (Spearman’s rank correlation, rho = 0.65, 
r2=0.437, P<0~0001). 
TABLE 1. Correlations* between oxygen cost diagram ratings and functional parameters, resting dyspnoea and Hospital 
Anxiety and Depression scores 
n Rho (*) p (*I 
Functional parameters 
FEVi (% of predicted) 45 - 0.068 0.6 
FVC (% of predicted) 45 -0.24 0.11 
Pa02 (kPa) 45 0.19 0.21 
PaC02 kPa) 45 -0.19 0.19 
6 min walking distance (m) 45 0.645 <0~0001 
Resting dyspnoea (Brog scale) 45 -0.18 0.24 
Hospital Anxiety and Depression scale 
Scores for anxiety 45 -0.59 O-0003 
Scores for depression 45 -0.06 0.73 
* Spearman’s rank correlation. For abbreviations see text. 
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Changes in pulmonary function and walk tests over this 
period were as follows: for FEVi: 1 f 8 % (- 16, + 33%); 
for FVC: - 1 f 17 % (-53, +44%); for Pa02 (kPa): 
-0.4+ 1.5 (-4+,+1.7); for PaC02 (kPa): -0.3$0.5 
(- 1.2, +0.4); for 6’W: - 181-80 m (- 197, +150). Changes 
in dyspnoea scores (Borg) were: - 1 f2.3 (-5, +5,7); 
changes in OCD were: -2113 (-25, +45). Average 
change in HAD scores was: -0.2 + 3 (- 13, +5) for 
anxiety, and -0.3 &- 3 (-4, +6) for depression. Although 
mean values for the above mentionned parameters were 
similar after follow-up, there was a wide variability in 
individual values for changes in all parameters tested, as 
shown in Fig. 3 for 6’ W. 
Correlations between changes in OCD ratings and 
changes in functional parameters, resting dyspnoea or 
HAD scores are shown in Table 2. No significant relation- 
ship was found between changes in OCD ratings and 
changes in FEVi, FVC, PaOz, PaCO*, distance walked on 
a 6’ W test, Borg resting dyspnoea scores, or HAD anxiety 
and depression scores. McNemar’s test was used to 
determine whether OCD ratings followed the same trend 
as other parameters recorded (i.e. did both parameters 
increase or decrease simultaneously?). OCD did not 
significantly reflect the trends in changes of FEVi, FVC, 
Pa02, PaCO*, distance walked on a 6’ W test, or HAD 
scores as noted in Table 2 and Fig. 3. However, although 
there was no significant relation between Borg scores and 
OCD scores in terms of magnitude of change (rho = - 0.13, 
P = 0.43), trends were significantly related (i.e. when resting 
dyspnoea increased, OCD scores decreased). 
Discussion 
The present study analyses the changes over a 1 yr period in 
pulmonary function tests, capacity of ambulation, resting 
dyspnoea and OCD ratings in patients treated by NIHV for 
predominantly restrictive disorders. To our knowledge, the 
only studies using the OCD in patients with NIHV were 
descriptive studies on smaller groups of patients (13;28). 
The present study is the first report of the use of OCD in a 
follow-up study of patients treated by NIHV. As in patients 
with COPD (13,16,17,29), OCD ratings were very signifi- 
cantly correlated with the distance walked during a 
6 min walk test, suggesting that patients reliably report 
their tolerance to physical activity with the OCD. However, 
this observation is misleading: because of the large 
variability around the regression line (Fig. 1); effort 
tolerance could not adequately be predicted from OCD 
scores on an individual basis. More importantly, our results 
suggest that the OCD may not correctly reflect changes in 
physical performances in follow-up studies: indeed, objec- 
tive changes in capacity of ambulation-as assessed by a 6’ 
walk test-could not be extrapolated from changes in OCD 
scores, either quantitatively or qualitatively. 
As previously mentioned, the OCD has been widely used 
in clinical trials, as a clinical endpoint in evaluating the 
efficacy of bronchodilators, inhaled corticosteroids, theo- 
phylline, ACE inhibitors or other treatments for dyspnoea 
in patients with asthma, COPD or chronic heart failure 
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FIG. 3. Relationship between changes in ‘oxygen cost 
diagram’ ratings and changes in distance walked during a 
standardized 6 min walk test and (Spearman’s rank 
correlation, rho = -0.046, P = 0.77). 
TABLE 2. Correlations between changes in oxygen cost diagram ratings and changes in functional parameters or resting 
dyspnoea 
n Rho (*) P (*) P value (McNemar’s test) 
Functional parameters 
AFEVi (% of predicted) 45 - 0.03 0.85 0.84 
AFVC (% of predicted) 45 -0.03 0.81 1 
APa (kPa) 45 - 0.004 0.98 0.83 
APaC02 (kPa) 45 0.03 0.94 0.99 
A6 min walking distance (m) 45 - 0.046 0.77 0.17 
Resting dyspnoea (ABorg score) 45 -0.13 0.43 0.030 
Hospital Anxiety and Depression scale 
Scores for anxiety 45 - 0.08 0.62 0.21 
Scores for depression 45 -0.12 0.43 1 
* Spearman’s rank correlation. For abbreviations see text. 
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(3-11). The OCD has also been used to compare levels of 
breathlessness and effort tolerance between specific groups 
of patients, i.e. ‘pink puffers’ vs. blue ‘bloaters’ (14), or 
COPD vs. patients with restrictive lung disease (13). In 
patients with terminal cancer, Farncombe reported that 
OCD was more sensitive than the Borg scale or a VAS scale 
in identifying subjects with a shortness of breath interfering 
with their quality of life (30). Results of OCD scores are 
well correlated with other clinical scales such as the Medical 
Research Council scale (MRC) and the Baseline Dyspnoea 
Index (BDI). Significant relationships have been documen- 
ted between the OCD and specific domains of HRQL 
questionnaires such as the SF-36, the St George Respira- 
tory Questionnaire (SGRQ) and the Chronic Respiratory 
Questionnaire (CRQ)(12,16,18,31). In fact, Hajiro et al. 
recently described the OCD as performing identically to 
the BDI, the MRC scale, and the dyspnoea scales of the 
CRQ or the,SGRQ in evaluating dyspnea in patients with 
COPD (18) 
Noseda et hl. suggested that the OCD is responsive to 
therapy (32). However, the validity of the OCD as an 
endpoint in clinical trials or. as an indicator of subjective 
exercise tolerance in follow-up studies should be ques- 
tionned. Indeed, Woodcock et al. (10) used the OCD in a 
study of the effect of promethazine and diazepam on 
dyspnoea in COPD patients: promethazine was associated 
with lower dyspnoea scores and higher walking distance in 
12 min than placebo; conversly, diazepam was associated 
with decreased walking distance in 12 min; however, OCD 
ratings did not differ between patients under placebo, 
diazepam or promethazine. ,Guyatt et al. (19) studied the 
effect of pulmonary rehabilitation on dyspnoea in 28 
patients with chronic lung disease: impact was highly 
significant using the Chronic Respiratory Disease Ques- 
tionnaire (CRQ) or the Transition Dyspnoea Index-an 
elaborate scale for scoring dyspnoea-but did not reach 
statistical significance when using the OCD. Guyatt et al. 
(7) also showed, in a randomized control trial of inhaled 
salbutamol and oral theophylline in COPD, that OCD 
failed to detect a clinical effect of theophylline on dyspnoea 
clearly detected by the CRQ, by a modified MRC category 
scale, and by an increase in 6 min walking distance. OCD 
changes were however significant for salbutamol. The 
conclusions of Guyatt et al. (7,19) were essentially that 
the OCD was less responsive than the CRQ or the TDI. The 
results of the present study-the largest follow-up study 
using the OCD published-question the usability of the 
OCD in follow-up studies in as much as changes in OCD 
did not even correctly identify the trends in changes of 
physical autonomy, in patients either increasing or decreas- 
ing significantly there results on a 6’ W test. This 
observation does not seem to be related to the population 
studied (patients with NIHV): in a previous study, we 
analysed the physical activity of patients under long-term 
oxygen therapy using a’podometer over a l-week period: 32 
patients were re-assessed after 1 yr; although OCD ratings 
were initially significantly correlated with average daily 
distance walked (rho =0.45, P=O.O003), there was no 
correlation between OCD and changes in ambulation; as 
in the present study, dCD did not accurately describe 
quantitatively or qualitatively the changes in physical 
activity over the 1 yr follow-up period (12). 
Conclusion 
The oxygen cost diagram is a simple tool for quantifying a 
patient’s perception of his tolerance to exercise and has 
been shown to be well correlated with objective measures of 
capacity of ambulation such as,the 6’ or 12’ walk test, or 
measures by podometer. These correlations however show a 
large variability around the regression line, and, as such, 
individual performances cannot be extrapolated from OCD 
ratings. Furthermore, the present study shows that the 
OCD does not accurately depict objective changes in 
capacity of ambulation-as assessed by 6 min walk test 
performances--either quantitatively or qualitatively. This 
study suggests that OCD does not appear appropriate to 
describe or even approximate changes in physical perfor- 
mance in clinical trials or follow-up studies: rather, it 
should be used only as a HRQL tool (i.e. a reflection of the 
patient’s perception), with the awareness of a possible 
discrepancy between objective changes in performance and 
OCD ratings. 
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